• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    How Investors May Respond To Natera (NTRA) Deepening Its MRD Role In Immunotherapy And Cancer Care

    Simply Wall St·08/18/2026 10:25:59
    Listen to the news
    • In recent days, Kupando Therapeutics announced a collaboration using Natera’s Latitude tissue-free MRD assay to monitor ctDNA dynamics in a Phase 1 trial of its KUP-101 immunotherapy across advanced skin cancers, while Natera also reported higher second-quarter 2026 revenue of US$752.75 million and a reduced net loss of US$66.97 million versus a year earlier.
    • These developments, alongside Natera’s raised 2026 revenue guidance, PMDA submission for Signatera in muscle-invasive bladder cancer, and expanded use of MRD testing in oncology trials, highlight how the company’s technology is being embedded more deeply into immunotherapy development and global cancer care pathways.
    • We’ll now explore how the Kupando MRD collaboration, and broader oncology test expansion, could reshape Natera’s investment narrative and risk profile.

    The latest GPUs need a type of rare earth metal called Dysprosium and there are only 28 companies in the world exploring or producing it. Find the list for free.

    Natera Investment Narrative Recap

    To own Natera, you need to believe its MRD and oncology platforms can convert growing clinical adoption into durable revenue while moving toward profitability. The Kupando Latitude deal and recent guidance raise do not materially change the near term focus, which remains on expanding reimbursed oncology use and managing high R&D and SG&A that still keep the business loss making.

    Among the recent announcements, the raised 2026 revenue guidance to US$2.85–2.91 billion is most relevant, because it frames how collaborations like Kupando’s Phase 1 trial, PMDA submissions and broader MRD use are feeding into management’s top line expectations. That guidance sits against ongoing pressure from high fixed costs and competition, which keeps execution on oncology growth and margin improvement at the center of the story.

    Yet even with this progress, investors still need to weigh the risk that sustained high expenses and intensifying competition could mean...

    Read the full narrative on Natera (it's free!)

    Natera's narrative projects $4.2 billion revenue and $300.7 million earnings by 2029.

    Uncover how Natera's forecasts yield a $282.14 fair value, a 10% downside to its current price.

    Exploring Other Perspectives

    NTRA 1-Year Stock Price Chart
    NTRA 1-Year Stock Price Chart

    While consensus leans on continued MRD adoption, the more pessimistic analysts highlight tightening regulation and reimbursement risk, even as they previously modelled about US$3.7 billion revenue and US$544 million earnings potential, reminding you that views can shift meaningfully as collaborations like Kupando’s evolve.

    Explore 4 other fair value estimates on Natera - why the stock might be worth as much as 93% more than the current price!

    Decide For Yourself

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    • A great starting point for your Natera research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
    • Our free Natera research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Natera's overall financial health at a glance.

    Contemplating Other Strategies?

    Opportunities like this don't last. These are today's most promising picks. Check them out now:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.